Skip to main content

Table 4 List of therapeutic candidates against COVID-19

From: SARS coronavirus 2: from genome to infectome

S. no Drug name Clinical trial Trial Treatment References
1. Pacritinib Phase 3 NCT04404361 Kinase inhibitor [170]
2. Enoxaparin Phase 3 NCT04401293 Antithrombotic [171]
3. Remdesivir + Baricitinib Phase 3 NCT04401579 Antiviral [172]
4. Remdesivir Phase 3 NCT04401579 Antiviral [172]
5. Hydroxychloroquine Phase 3 NCT04410562 Antimalarial [173]
6. Favipiravir + Hydroxychloroquine Phase 3 NCT04411433 Antiviral [174, 175]
7. ASC09 + Oseltamivir Phase 3 NCT04261270 Antiviral [176]
8. ASC09 + Ritonavir NA NCT04261907 Antiviral [176]
9. Tocilizumab (IL-6) Phase 3 NCT04412772 Monoclonal antibodies [177]
10. Anakinra Phase 3 NCT04412291 Anti-inflammatory [178]
11. Ivermectin Completed NCT04422561 Antiparasitic [179]
12. Budesonide dry powder inhaler Phase 2 NCT04416399 Corticosteroid [180]
13. LY3819253 Phase 3 NCT04427501 Corticosteroid [181]
14. Atazanavir and dexamethasone Phase 3 NCT04452565 Corticosteroid and antiviral [182]
15. Colchicine Phase 2 NCT04326790 Anti-inflammatory [183]
16. Corticosteroid Phase 3 NCT04381936 Corticosteroid [184]
17. Azithromycin Phase 3 NCT04381936 Antibacterial [184]
18. Convalescent plasma Phase 3 NCT04425915 Convalescent plasma [130]
19. NA-831 and dexamethasone Phase 3 NCT04452565 Corticosteroid [182]
20. Camostat Mesilate Phase 2 NCT04470544 Protease inhibitor [81]